Money and Finance
Happy Spring. Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors:
- Glaxosmithkline - Stout Yield Worth The Risks?
GlaxoSmithKline is the second stock that I added to the Wide Moat Dividend (WMD) portfolio. The positives are pretty clear - a 5.6% yield really stands out in this yield parched world. All the better when it comes from a defensive company like Glaxo and...
- Second & Third Picks In Wmd Portfolio - Glaxosmithkline & Ibm
The more real they are, the more fun blogs are to follow. So in that spirit, rather than talking about ideas in the abstract I maintain a hypothetical portfolio to track ideas where I'll semi-regularly (and hypothetically) invest and track buying...
- High Yield Reads - 7/13/14
Summary of recents posts and pieces of interest, sometimes enduring, to investors: Josh Peters on dividend and buyback debate: the record for buybacks was set in 2007 near previous market highs, then when prices improved companies were concerned with...
- High Yield Reads - 4/5/14
Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors: Base Hit Investor on Markel - as you might guess from the title, I am main interested in dividend stocks, but there are one or two exceptions, Berkshire comes...
- High Yield Reads - 3/15/14
Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors: "The Most Important Metric for Dividend Investors" by Todd Wenning. Put this one in the enduring interest category. Investors of all stripes need to know which...
Money and Finance
High Yield Reads 3/22/14
Happy Spring. Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors:
- Jason Zweig: on the downsides of share buybacks. Looking at the Russell 3000 he reports that after the index went up 33.5% and trades at a P/E of 17, buybacks increased in 2013 by 21%. This is more evidence in the ongoing debate that buybacks are certainly not always better than dividends.
- From his fund, one of Neil Woodford's largest holdings was Astra Zeneca. From trailing its peers for years, in the last six months its stock has been on a tear. Yielding 4.4% it now trades much closer the richly valued Roche (another one from Woodford's stable).
- What is the world's riskiest stock market? No surprise here - Russia. So far this year $600M has exited Russian ETFs. At the end of February, the P/E for Russian companies is 6.5.
- Jason Zweig shares the greatest investing cartoon of all time.
- Dividend Growth Investor analyzes spirits maker extraordinaire Diageo. Its the kind of high quality company that unless we're talking 2008-9, never really trades for a cheap valuation. But the quality metrics are flat out great - 30+% Operating Margins, Return on Equity from the high 30 into the 40s. And its delivered growth - an annualized return of 12.4% over the last decade. They raised their dividend by 8.8% which makes 15 years of dividend increases. With a P/E at 17, that does not seem super high for the level of quality and sustained growth Diago provides
- Todd Wenning sold Tesco for a loss. Like engineers, investors can learn a lot from mistakes, especially if there is a pattern that you can recognize and avoid in future. Losses are no laughing matter, but have to wonder if Todd was worried about Tesco's recent Red Headed League issue. (Note: Kidding)
- Base Hit Investor on pricing power. Pricing power is a key factor in quality and its important to understand both its power and the limits - all good things must end
- Good story on Buffett & Quicken's Billion Dollar Bracket. Reilly estimates that Berkshire received $15M which Buffett indicated was close. The contest did not last long, all perfect brackets eliminated before end of the second day of the tournament.
- Glaxosmithkline - Stout Yield Worth The Risks?
GlaxoSmithKline is the second stock that I added to the Wide Moat Dividend (WMD) portfolio. The positives are pretty clear - a 5.6% yield really stands out in this yield parched world. All the better when it comes from a defensive company like Glaxo and...
- Second & Third Picks In Wmd Portfolio - Glaxosmithkline & Ibm
The more real they are, the more fun blogs are to follow. So in that spirit, rather than talking about ideas in the abstract I maintain a hypothetical portfolio to track ideas where I'll semi-regularly (and hypothetically) invest and track buying...
- High Yield Reads - 7/13/14
Summary of recents posts and pieces of interest, sometimes enduring, to investors: Josh Peters on dividend and buyback debate: the record for buybacks was set in 2007 near previous market highs, then when prices improved companies were concerned with...
- High Yield Reads - 4/5/14
Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors: Base Hit Investor on Markel - as you might guess from the title, I am main interested in dividend stocks, but there are one or two exceptions, Berkshire comes...
- High Yield Reads - 3/15/14
Summary of recents posts and pieces of interest, sometimes enduring, to dividend investors: "The Most Important Metric for Dividend Investors" by Todd Wenning. Put this one in the enduring interest category. Investors of all stripes need to know which...